舒泰神(300204.SZ)治疗乙型肝炎病毒感染相关疾病的基因药物申报新药临床试验
格隆汇6月18日丨舒泰神(300204.SZ)公布,公司及全资子公司北京三诺佳邑生物技术有限责任公司(“三诺佳邑”)于2019年06月18日向国家药品监督管理局提交了关于治疗乙型肝炎病毒感染相关疾病的基因药物(项目名称:STSG-0002注射液)的新药临床试验申请。
STSG-0002注射液是具有自主知识产权的1类新药,是基于核糖核酸干扰(RNAi)机制用于治疗乙型肝炎病毒感染相关疾病的基因药物,属于治疗用生物制品I类。乙型肝炎病毒(HBV)感染是严重威胁全球健康的主要问题之一,全球HBV感染率为3.5%。中国是HBV高发国家,HBsAg(乙型肝炎表面抗原)携带率为7.18%,推算慢性HBV感染者约有9300万,其中约2000万为慢性乙肝患者,给患者的生活带来巨大的痛苦和经济负担。目前在国内外抗HBV的治疗药物主要为核苷(酸)类和干扰素类,现有核苷(酸)类药物效应靶位在HBV病毒聚合酶;干扰素需反复注射给药,持续给药应答率低。探寻更为有效的新型治疗方案是国内外治疗HBV相关疾病的迫切的临床需求。
STSG-0002注射液项目的研发成功将有效解决现有乙型肝炎患者抗病毒治疗方案不能直接降低HBsAg(乙型肝炎表面抗原)等HBV相关结构蛋白和调节蛋白的问题,有效降低HBV携带者肝脏HBV复制带来的慢性炎症,有效阻止慢性乙型肝炎患者向肝硬化、肝癌等重型肝病的进展,并将对HBV感染相关重症疾病带来新的治疗手段,具有良好的应用前景。STSG-0002属于全新靶点,全球范围内尚无该靶点基因产品上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.